A Comparison of FLT to FDG PET/CT in the Early Assessment of Chemotherapy Response in Stage IB-IIIA Resectable NSCLC
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
This study is being done to compare a special type of Positron Emission Tomography (PET) scan
with CT scan in patients with surgically removable lung cancer to see which method is more
useful in measuring a response to treatment. A PET scan uses small amounts of radioactive
material injected into the blood to show the internal workings of the body. In this study, we
will use two radioactive materials: 18F-FLT (referred to as FLT) and 18F-FDG (referred to as
FDG). FDG is used routinely in the staging of lung cancer and is approved by the FDA for that
purpose. FLT is used in the special type of PET scan being assessed by this study. In
addition the study will assess the effects of the combination of docetaxel and cisplatin
(chemotherapeutic drugs) on certain pathological characteristics of the tumor. The
combination of docetaxel and cisplatin is approved by the Food and Drug Administration (FDA)
for the treatment of advanced/metastatic NSCLC (non-small cell lung cancer). It is not
approved for use in patients who have surgically removable NSCLC. In such cases cisplatin is
used as a single drug therapy before surgery. The FDA is allowing the use of docetaxel along
with cisplatin in this research study.